Five of Sichuan Kelun Pharmaceutical's (SHE:002422) drugs were included in China's national basic medical insurance catalog, according to a Shenzhen bourse filing on Tuesday.
The drugs include meropenem or sodium chloride injection and cetuximab N01 injection.
The pharmaceutical company's shares fell less than 2% during the midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments